SOURCE: Large Scale Biology

March 21, 2005 02:00 ET

Predictive Diagnostics, Inc. Announces Collaboration With the University of Utah Research Foundation to Develop Diagnostic Tests for Pregnancy Complications

VACAVILLE, CA -- (MARKET WIRE) -- March 21, 2005 -- Predictive Diagnostics, Inc. (PDI), a wholly-owned subsidiary of Large Scale Biology Corporation (NASDAQ: LSBC) announced today that it has a collaboration with the University of Utah Research Foundation (UURF) to identify biomarkers from a simple maternal blood test for the early diagnosis of pregnancy-related complications and disorders such as pre-term birth and preeclampsia. Under the collaboration, UURF will provide PDI with blood samples that PDI will analyze using its proprietary BAMF™ technologies to identify and validate blood tests for the diagnosis, treatment and monitoring of such conditions.

Further information about Predictive Diagnostics, Inc. can be found on the company's website (www.predictivediagnostics.com).

About Large Scale Biology Corporation

Large Scale Biology Corporation is a biotechnology company developing and biomanufacturing biotherapeutics, diagnostic tests, vaccines and industrial proteins for important life science industry markets. Corporate headquarters, molecular biology and product design laboratories, and Predictive Diagnostics, Inc., are located in Vacaville, California, and the Company's bioprocess development and commercial-scale biomanufacturing facilities are located in Owensboro, Kentucky. In addition to its class-leading internal capabilities, LSBC relies on a network of industry, government and academic collaborators throughout the US and Europe to achieve rapid, commercially relevant product discovery, optimization and manufacturing. For more information about Large Scale Biology Corporation, visit the Company's website at www.lsbc.com.

This release contains forward-looking statements about applications of LSBC and Predictive Diagnostics' technologies and potential market opportunities for our diagnostic tests. These forward-looking statements involve risks, uncertainties and situations that may cause our actual results to differ materially from those implied by these statements, including our ability to commercialize applications of our technologies, the ability of our collaborators to generate demand for the diagnostic applications, the effectiveness of our and our collaborators' technologies to produce specific diagnostics or provide services and/or in a cost-effective manner, any difficulties or delays in obtaining regulatory approval to test and market such diagnostics or services, and the requirement of substantial funding for us to preserve our technology base and diagnostic applications. We cannot guarantee future results. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this release. For a further list and description of such risks and uncertainties see the reports filed by Large Scale Biology Corporation with the Securities and Exchange Commission, including our reports on Forms 10-K and 10-Q. Except as required by law, we do not undertake to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

LSBC® and BAMF™ are trademarks of Large Scale Biology Corporation.

Contact Information